Drug Status: Marketed Drug
Symbicort provides the inhaled corticosteroid budesonide (Pulmicort) and the rapid and long-acting bronchodilator formoterol (Oxis) in a single inhaler (Turbuhaler).
Symbicort is indicated for the maintenance treatment of asthma in adults and children aged 6 years and above, where the combination of an inhaled corticosteroid and a long-acting beta 2- agonist is appropriate.
For further information on Symbicort and links to other product specific and disease area websites please click here.
Please consult the prescribing information for the country concerned on the approved use of drug.
- collapse A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
- collapse Efficacy and Safety Study of Symbicort Turbuhaler Versus Oxis Turbuhaler in Chronic Obstructive Pulmonary Disease (COPD) Patients
- collapse A comparison of Symbicort SMART (160/4.5?g) and Symbicort Turbuhaler 160/4.5 ?g, plus terbutaline Turbuhaler 0.4 mg as needed, for treatment of asthma - a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients from 16 years
- collapse Real life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients across Asia: SMARTASIA
- collapse A Pharmacoepidemiological study in patients who use Symbicort Turbuhaler as maintenance and reliever therapy capturing over-use and under-use via the General Practice Research Database.
- collapse A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled, multicenter, dose-finding study comparing single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pMDI and Foradil® 12 μg evaluating the relative bronchodilating effects and safety in children, a
- collapse Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma
- collapse A randomized, multicenter, placebo and active-controlled, single-dose, 4-period, crossover study to evaluate the bronchodilating effect of SYMBICORT pMDI versus Advair Diskus and Ventolin HFA.
- collapse A randomized, multicenter, placebo and active-controlled, single-dose, 4-period, crossover study to evaluate the bronchodilating effect of SYMBICORT pMDI versus Advair Diskus and Ventolin HFA.
- collapse A randomized, multicenter, open-label, active-controlled, single-dose, 5-period, incomplete block, cross-over study to evaluate the relative bronchodilating effects of formoterol when administered via Symbicort pMDI or Oxis Turbuhaler to adults with stable asthma.
